Takeda Chemical Industries Ltd.: Lessons from a Japanese Pharma Major
|
|
ICMR HOME | Case Studies Collection
Case Details:
Case Code : BSTR074
Case Length : 20 Pages
Period : 2003
Organization : Takeda Chemical Ltd.
Pub Date : 2003
Teaching Note :Not Available
Countries : Japan
Industry : Automobile
To download Takeda Chemical Industries Ltd.: Lessons from a Japanese Pharma Major case study (Case Code: BSTR074) click on the button below, and select the case from the list of available cases:
Price:
For delivery in electronic format: Rs. 500;
For delivery through courier (within India): Rs. 500 + Rs. 25 for Shipping & Handling Charges
»
Business Strategy Case Studies
» Business Strategy Short Case Studies
» View Detailed Pricing Info
» How To Order This Case
» Business Case Studies
» Area Specific Case Studies
» Industry Wise Case Studies
» Company Wise Case Studies
Please note:
This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source.
|
|
<< Previous
Introduction Contd...
Takeda owned/produced four highly successful drugs [Actos (for treating diabetes), Lansoprazole (for treating ulcers), Lupron Depot (for treating prostate cancer) and Cendesartan (for hypertension)]. In addition, the company had as many important new drugs in the pipeline as some of the world's biggest pharmaceutical companies. Keeping in view the growth oriented initiatives taken by the company, industry observers stated that Takeda was all set to emerge as a major global player in the near future. It already was one of the fastest growing Japanese pharmaceutical companies, a fact amply reflected in its strong financial performance over the years. In 2002, Takeda posted consolidated profits of $8.9 billion. It was the only Japanese company that had posted record profits and sales for 10 consecutive years (Refer Exhibit I for a 10-year summary of Takeda's key financial data).
Background Note
|
Takeda was established in 1781 in Japan as a small wholesale outfit dealing in medicines in Doshomachi, Osaka (a commercial center for medicine trade in Japan) by Chobei Takeda I. The wholesaler sold traditional Japanese and Chinese medicines (bought from bigger wholesalers) to local doctors and medicine retailers. In the decades that followed, Takeda emerged as a dominant player even as many big and small wholesalers and retailers mushroomed in the country. The Takeda family had been in the business of selling traditional medicines for over four generations. This business continued until 1871 when Chobei Takeda IV and a group of other medicine retailers decided to sell Western medicine as well.
|
|
Chobei Takeda IV formed co-operative unions in Yokohama for purchasing foreign
medicines and began transactions with foreign trading companies.
|
|
The first
Western medicines imported at that time included Quinine (used for
treating malaria) and Phenol (used for treating cholera). By the mid-1890s, Takeda was importing drugs directly from US, England, Germany, Spain and many other countries. In 1895, the drugs selling business was extended to manufacturing drugs with a manufacturing facility being set up at Osaka. The factory produced drugs like Subgallate,
used in treating diarrhea and Quinine Hydrochloride, used in treating
malaria. By 1907, Takeda obtained exclusive sales rights from Bayer, a
German pharmaceutical company, to sell its products in Japan. By the
turn of the 20th century, Takeda shifted its primary focus to Western
medicines... |
Excerpts >>
|
|
